RNK08954 Drug Asset Due Diligence Report 2026

This RNK08954 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether RNK08954 can convert its Small molecule drug profile and KRAS G12D biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	RNK08954 (query alias: RNK08954)
Modality / target	Small molecule drug; KRAS G12D; KRAS G12D inhibitors
Highest global status	Phase 2
Originator	Ranok Therapeutics Co., Ltd.
Active developers	Ranok Therapeutics Co., Ltd.

The MCP disease footprint includes Endometrial Carcinoma, Ovarian Cancer, Uterine Cervical Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20263173	Phase 2	Not yet recruiting	120	Primary endpoint not disclosed in English source
NCT07441174	Phase 1/2	Recruiting	92	Primary endpoint not disclosed in English source
NCT07334262	Phase 1	Not yet recruiting	24	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of RNK08954 in patients with advanced solid tumors with a KRAS G12D mutation.

Phase 1; n=42; evaluation: Positive. Reported fields: TRAE(Grade ≥ 3) = diarrhea (5%), vomiting (2%), decreased appetite (5%), decreased white blood cells (2%), and hypokalemia (5%). ; TRAE(Grade ≥ 3) = diarrhea (5%), vomiting (2%), decreased appetite (5%), decreased white blood cells (2%), and hypokalemia (5%).

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

RNK08954 addresses Endometrial Carcinoma, Ovarian Cancer, Uterine Cervical Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 13 matched transaction record(s) under the scope “target-level comparable: KRAS G12D.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: KRAS G12D records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-08-10	Revolution Medicines granted BeOne exclusive rights in select Asian markets to develop and commercialize or solely commercialize, depending on the market, four clinical-stage RAS(ON) inhibitors.	Phase 3	Financial terms not disclosed
2025-08-12	Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology	IND Approval	US$1,300.0M stated total
2024-05-02	BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO